{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:06:54Z","timestamp":1789204014284,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijmmb.2026.101177","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:22:50Z","timestamp":1781763770000},"page":"101177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combating antimicrobial resistance in ESBL- and AmpC-producing Enterobacterales: In vitro evaluation of cefepime\u2013enmetazobactam"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2058-7456","authenticated-orcid":false,"given":"Pooja","family":"Haleangadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-0097","authenticated-orcid":false,"given":"M.","family":"Suchitra Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-975X","authenticated-orcid":false,"given":"Anisha Maria","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijmmb.2026.101177_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/antibiotics11020200","article-title":"Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics","volume":"11","author":"Murugaiyan","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijmmb.2026.101177_bib2","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.2147\/IDR.S290835","article-title":"Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health","volume":"13","author":"Majumder","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"11","key":"10.1016\/j.ijmmb.2026.101177_bib3","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/biomedicines11112937","article-title":"Extended-Spectrum \u03b2-Lactamases (ESBL): challenges and opportunities","volume":"11","author":"Husna","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101177_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/antibiotics9020061","article-title":"Carbapenem-sparing strategies for ESBL producers: when and how","volume":"9","author":"Karaiskos","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijmmb.2026.101177_bib5","first-page":"186","article-title":"Prevalence of various beta-lactamases in Enterobacteriaceae in a tertiary care hospital in South India: a cross-sectional study","volume":"2021","author":"Roopashree","year":"2021","journal-title":"IP Int J Med Microbiol Trop Dis"},{"key":"10.1016\/j.ijmmb.2026.101177_bib6","article-title":"Global distribution and incidence of multidrug resistant and ESBL producing Escherichia coli: an observational study of the ATLAS dataset","volume":"35","author":"Al-Mustapha","year":"2025","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.ijmmb.2026.101177_bib7","series-title":"Antimicrobial Resistance Research & Surveillance Network (AMRSN) - annual report 2024","year":"2025"},{"key":"10.1016\/j.ijmmb.2026.101177_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2024.04.014","article-title":"Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates","volume":"38","author":"Morrissey","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"7","key":"10.1016\/j.ijmmb.2026.101177_bib9","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1128\/AAC.00089-11","article-title":"Exploring the inhibition of CTX-M-9 by \u03b2-Lactamase inhibitors and carbapenems","volume":"55","author":"Bethel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijmmb.2026.101177_bib10","first-page":"15","article-title":"Carbapenem resistance: overview of the problem and future perspectives","volume":"3","author":"Meletis","year":"2016","journal-title":"Ther Adv Infect Dis"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101177_bib11","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/microorganisms11081912","article-title":"The challenge of overcoming antibiotic resistance in carbapenem-resistant gram-negative bacteria: \u201cattack on Titan.\u201d","volume":"11","author":"Mancuso","year":"2023","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.ijmmb.2026.101177_bib12","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijmmb.2026.101177_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acsinfecdis.4c00982","article-title":"Invention of enmetazobactam: an Indian triumph in antimicrobial drug discovery","volume":"11","author":"Paul-Satyaseela","year":"2025","journal-title":"ACS Infect Dis"},{"issue":"13","key":"10.1016\/j.ijmmb.2026.101177_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute Pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101177_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: first approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101177_bib16","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2025"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101177_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.ijmmb.2026.101177_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00327-19","article-title":"Trends in and predictors of carbapenem consumption across north American hospitals: results from a Multicenter survey by the MAD-ID research network","volume":"63","author":"Rhodes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijmmb.2026.101177_bib19","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations for treatment of bloodstream infections due to Extended-Spectrum-\u03b2-Lactamase-Producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijmmb.2026.101177_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/antibiotics13030260","article-title":"Role of \u03b2-Lactamase inhibitors as potentiators in antimicrobial chemotherapy targeting gram-negative bacteria","volume":"13","author":"Zhang","year":"2024","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.ijmmb.2026.101177_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116993","article-title":"In-vitro activity of cefepime\/enmetazobactam against extended spectrum beta-lactamases and\/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India","volume":"113","author":"Bakthavatchalam","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.ijmmb.2026.101177_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ijmmb.2026.101177_bib23","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-Lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.ijmmb.2026.101177_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ijmmb.2026.101177_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: cefepime and AAI101 as a potent \u03b2-Lactam\u2212\u03b2-Lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101177_bib26","first-page":"393","article-title":"Comparison of in vitro activity of cefepime-enmetazobactam and other carbapenem-sparing agents for gram-negative uropathogens","volume":"11","author":"Ramakrishnan","year":"2025","journal-title":"IP Int J Med Microbiol Trop Dis"},{"issue":"10","key":"10.1016\/j.ijmmb.2026.101177_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101177_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00926-21","article-title":"Sigmoid emax modeling to define the fixed concentration of enmetazobactam for MIC testing in combination with cefepime","volume":"65","author":"Knechtle","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijmmb.2026.101177_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime-enmetazobactam against gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101177_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","volume":"25","author":"Belley","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:21:08Z","timestamp":1789201268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085726001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S0255085726001350"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101177","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combating antimicrobial resistance in ESBL- and AmpC-producing Enterobacterales: In vitro evaluation of cefepime\u2013enmetazobactam","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Indian Association of Medical Microbiologists.","name":"copyright","label":"Copyright"}],"article-number":"101177"}}